Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
January 06, 2025 16:30 ET | Source: Generation Bio Co. Novel programs…
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:…
Vor Bio Announces $55.6 Million Private Placement
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of…
Bio Protocol (BIO), a DeSci Project, Will Be Innitially Listed on CoinW Exchange
Dubai, UAE , Dec. 25, 2024 (GLOBE NEWSWIRE) -- CoinW, the world's…
Orca Bio Presents Clinical Results on Use of Orca-Q without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
Orca-Q allogeneic T-cell immunotherapy with no GvHD prophylaxis in patients with matched…
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Treatment effects sustained through long-term follow-up of beyond 10 years in the…
US FDA Grants Orphan Drug Designation to EXG110, a Novel Gene Therapy for Fabry Disease
Company also Provides Updates on wet Age Related Macular Degeneration and Rare…
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical…
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024 13:30 ET | Source: 89bio, Inc. SAN FRANCISCO, Nov.…
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
Improved operating performance by reducing net loss by $52.5 million; reported net…